BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • May 2023
  • August 2021
  • July 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Browsing Tag

Sigilon Therapeutics

1 post

About Sigilon Therapeutics

Sigilon Therapeutics is a biopharmaceutical company that develops functional cures for patients with a range of chronic illnesses by using the human cell’s power through its Shielded Living Therapeutics™ platform.

Sigilon’s product candidates are non-viral engineered cell-based therapies that aim to create the necessary proteins, enzymes, or other therapeutic molecules for people with chronic illnesses such as lysosomal diseases and diabetes.

The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, designed to reduce and shield them from immune rejection. Sigilon was founded by Flagship Pioneering in 2016 in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Sigilon Therapeutics Company Vision

Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.

Treatments based on the Sigilon Therapeutics platform combine advanced cell engineering with cutting-edge innovations in biocompatible materials to pioneer a new class of therapeutics, Shielded Living Therapeutics™ (SLTx), that provide durable, controllable, and safe treatment for serious chronic diseases.

In April 2018, Sigilon and Eli Lilly announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.

Sigilon Therapeutics Technology

The company’s Shielded Living Therapeutics™ platform combines proprietary Afibromer™ technology with novel, engineered human cell lines that can produce a wide range of proteins aimed at treating serious chronic disorders.

Sigilon Therapeutics Pipeline

Sigilon’s pipeline of products includes hemophilia, lysosomal storage diseases, and, in collaboration with Eli Lilly, type 1 diabetes.

Sigilon is currently carrying out preclinical studies in other chronic disease indications while the primary programs rapidly advance toward clinical use.

The company also believes it will find uses for Afibromer™ beyond cell therapy such as the potential to reduce the incidence of fibrosis when using glass, plastic, or metal in coronary stents and other medical implants.

Sigilon Therapeutics Provides Update on Strategic Reprioritization
BioTech Health X
  • May 22, 2023

Biotech NewsSigilon Therapeutics Provides Update on Strategic Reprioritization

  • 2 minute read
San Francisco, California-based biotechnology firm Sigilon Therapeutics, Inc. (NASDAQ: SGTX) has announced a strategic re-prioritization to enable the…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
  • Advanced Chemotherapy Technologies Receives $4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
  • Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
  • Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle (PTV)
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • May 31, 2023
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    • May 31, 2023
    Advanced Chemotherapy Technologies Receives $4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
    Advanced Chemotherapy Technologies Receives 4 Million NIH Grant to Pursue Pancreatic Cancer Treatment
    • May 31, 2023
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • May 31, 2023
    Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial
    Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head Neck Patients in Phase 3 Trial
    • May 31, 2023
    Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle (PTV)
    Denali Therapeutics Announces Scientific Journal Publication of Preclinical Proof of Concept for Protein Transport Vehicle PTV
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • May 31, 2023
  • 11/19/21
    • May 30, 2023
  • Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery T Cell Receptors
    Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors
    • May 29, 2023
Categories
  • BioTech CEO Interviews (4)
  • Biotech Info (1)
  • Biotech News (45)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top